Agilent - Breakthroughs in Immunotherapy- 2019 - 25

Roundup

Quantifying Immune-Cell
Mediated Killing

t present, most of the commercially available cancer immunotherapies employ monoclonal antibodies or cancer vaccines, but a different kind of cancer immunotherapy, adoptive cell transfer
(ACT), is progressing rapidly. ACT usually involves the harvesting of patients' own immune cells,
expanding these cells (or engineered versions of them), and then reintroducing them to patients.
ACT-based treatments pose serious developmental challenges, not the least of which is the need
to evaluate the cancer-killing abilities of the immune cells. In addition to being robust and simple,
the ideal in vitro assay closely mimics activity in vivo. The ideal in vitro assay must also predict long
term behavior in animal models, and ultimately, in human patients. To facilitate the study of immune
cell-mediated killing, ACEA Biosciences - now a part of Agilent Technologies - has developed the
xCELLigence® Real-Time Cell Analysis (RTCA) platform.
The RTCA platform is described below, the main text of which is devoted to showing how the
RCTA platform is helping advance real-world projects. In this article, several key opinion leaders
tell GEN how they are using the RTCA platform.
GEN: Why is there such a great disparity in the potency of current cancer immunotherapies
between patients or between patient subpopulations?
Dr. Anderson: Two factors, genetics and the tumor microenvironment, are major focuses of investigation. In addition, adaptive resistance is not very well understood yet, but it's going to be a problem
for many types of immunotherapy. Cancers have adapted to evade treatment strategies in the past,
25

| GENengnews.com

Additional Info

View this
webinar on
demand: "The
Next Generation
of CAR-T Cells"

https://go.aceabio.com/l/492941/2018-10-03/n8y8yy http://www.GENengnews.com

Agilent - Breakthroughs in Immunotherapy- 2019

Table of Contents for the Digital Edition of Agilent - Breakthroughs in Immunotherapy- 2019